[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"breathlessness\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:breathlessness":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,41,69,97,122,152,175],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100635457","management-of-dyspnea-with-high--flow-nasal-therapy-100635457",false,"NCT07552935","Management of Dyspnea With High- Flow Nasal Therapy","HFNTpal","Inclusion Criteria:\n\n* The patient is in palliative care (ICD-10 diagnostic code Z51.5 palliative care)\n* Age ≥ 18 years\n* Ability to understand the study and provide informed consent to participate\n* Significant breathlessness (NRS = Numeric Rating Scale ≥ 4).\n* The treating physician has assessed that the patient would not benefit from treatment in intensive care unit or monitor unit.\n* The treating physician has assessed that the patient would not benefit from invasive mechanical ventilation (intubation) or cardiopulmonary resuscitation.\n\nExclusion Criteria:\n\n* Decreased level of consciousness, delirium, or other lack of cooperation that prevents participation.\n* Respiratory support other than HFNT is required.\n* The patient has received HFNT during the same admission to palliative care ward or hospice.\n* The cause of dyspnea can be treated immediately.\n* Inability to provide informed consent to participate.","ALL","18 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"NA","Dyspnea in patients with incurable illness is a difficult symptom. Therefore, there is a need to identify new effective treatment modalities. Previous studies suggest that high-flow nasal therapy delivered via a nasal cannula (HFNT = High-Flow Nasal Therapy) may alleviate dyspnea, and similarly that directing airflow toward the face can provide relief. HFNT has been studied very little in hospice settings and on palliative care wards. The aim of this study is to determine whether HFNT is a feasible and effective treatment for relieving dyspnea in patients receiving palliative care.\n\nPatients will be recruited from the Hatanpää Palliative Care Ward and the Pirkanmaa Hospice, Tampere, Finland. The target is to recruit approximately 30-40 patients. The inclusion criteria are: age ≥18 years, ability to understand the study and provide informed consent to participate, a palliative treatment approach, and significant dyspnea.\n\nEach patient receives HFNT and fan therapy in which airflow will be directed toward the patient's face. Both treatments will last 30 minutes. Patient symptoms will be asked after the treatments. In addition, patients will be asked to rate the overall benefit they experienced from the intervention and any side effects. The primary endpoint is the relief of dyspnea with HFNT compared with fan therapy.\n\nThe study will be conducted in accordance with laws, regulations, and guidelines governing medical research, as well as good scientific practice and research ethics. The study does not involve significant risks or measurements or sampling procedures that would cause additional discomfort. All other care for the patient will be provided according to the standard practices of the treating unit, and participation in the study will not limit any necessary treatments. Identifiable information will not be disclosed for use outside the research group. Results will be reported in a manner that does not allow patients to be identified. The Ethics Committee of the Wellbeing Services County of Pirkanmaa has approved the study.\n\nIf successful, the study will significantly improve the care of the patients in palliative care.",[26,27],"Palliative Care","Breathlessness","RECRUITING","2026-06-25",{"date":31,"type":32},"2026-06-30","ACTUAL",{"date":34,"type":32},"2026-06-01",{"date":36,"type":20},"2029-12-31",{"name":38,"class":39},"Tampere University Hospital","OTHER",2,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100634738","the-physiotherapy-assessment-of-breathing-pattern-disorder-100634738","NCT07543588","The Physiotherapy Assessment of Breathing Pattern Disorder","An Evaluation of Physiotherapy Assessment; A Mixed Methods Study to Evaluate the Physiotherapy Assessment of Breathing Pattern Disorder","PHAB","Inclusion Criteria (Breathing Pattern Disorder group)\n\n* Adults aged above 18 years\n* Outpatient referrals for 'unexplained breathlessness' or possible breathing pattern disorder\n* Primary BPD (no other significant respiratory or cardiology diagnosis)\n* Secondary BPD (patients with a diagnosis of asthma)\n* Able to complete up to four sessions of outpatient physiotherapy intervention Exclusion Criteria\n* Patients with a respiratory diagnosis including COPD, ILD, Bronchiectasis and Cystic Fibrosis or structural heart disease\n* Pregnancy\n* Unable to give informed consent\n* Anyone currently participating in pulmonary\u002Fcardiac rehabilitation\n* Anyone receiving specialist ENT speech and language therapy for Upper airway symptoms",true,{"count":51,"type":20},150,"OBSERVATIONAL","This study aims to evaluate a clinical tool called the Breathing Pattern Assessment Tool (BPAT), which is used by physiotherapists to assess breathing pattern disorder (BPD). BPD is a condition where breathing is inefficient or out of sync with the body's needs, leading to symptoms such as breathlessness.\n\nThe study will investigate whether the BPAT is a reliable and accurate way to identify and assess BPD, and whether it can be used to monitor changes over time, particularly following physiotherapy treatment. It will also compare BPAT scores with other commonly used questionnaires that measure breathlessness and breathing symptoms.\n\nParticipants will include patients with BPD, patients with asthma, and healthy individuals. Patients with BPD will attend physiotherapy sessions as part of their usual care, during which their breathing will be assessed using the BPAT at different time points, including before and after treatment. Healthy participants will attend a single assessment visit, and asthma participants' data will be collected from routine clinical care.\n\nThe study will also explore whether BPAT scores change following treatment and whether these changes reflect improvements reported by patients and clinicians.\n\nIn addition, a small number of patients and physiotherapists will be invited to take part in interviews to share their experiences of the assessment process and treatment. This will help understand whether the BPAT is acceptable and useful in clinical practice.\n\nOverall, this study aims to improve how breathing pattern disorder is assessed and monitored, which may help guide better treatment for patients in the future.",[55,27],"Breathing Pattern Disorder",[27,55,57,58],"Physiotherapy","Assessment","2026-04-28",{"date":61,"type":32},"2026-05-05",{"date":63,"type":32},"2024-12-10",{"date":65,"type":20},"2026-05-01",{"name":67,"class":39},"Royal Brompton & Harefield NHS Foundation Trust",1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":81,"conditions":82,"keywords":85,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":68},"100552485","phase-3-reducing-breathlessness-with-dronabinol-in-copd-patients-100552485","NCT06473701","Reducing Breathlessness With Dronabinol in COPD Patients","BONG: Reducing Severe Breathlessness With Dronabinol in the Severe and Very Severe Chronic Obstructive Pulmonary Disease Patient Group - A Randomized, Double-Blind, Placebo-Controlled, Crossover Study","BONG","Inclusion Criteria:\n\n* Refractory dyspnea despite optimal treatment\n* COPD (GOLD 3,4)\n* Breathlessness corresponding to mMRC score ≥ 3\n* Informed written consent\n* Age ≥ 18 years\n* Cognitive relevant, of legal age\n* Understands and speaks Danish\n* For fertile women defined by amenorrhea for less than 12 months: negative HCG before entry into the trial\n* For fertile and sexually active subjects: use of safe contraception during medication intake and 4 weeks after: intrauterine device (IUD) or hormonal contraception (oral contraceptive pill, implant, transdermal patch, vaginal ring or depot injection).\n\nExclusion Criteria:\n\n* Ongoing infection or exacerbation of COPD within the last month (30 days)\n* Regular treatment with THC or CBD within 1 month (30 days)\n* Life expectancy less than 3 months (90 days)\n* Treatment with medicines that, according to the summary of product characteristics, are strong inhibitors or inducers of CYP3A4, CYP2C9 or CYP2C19\n* History of or current evidence of significant medical or psychiatric disorder that is considered by the investigator to put the subject at greater risk of experiencing an adverse event\n* Current or past substance abuse where the investigator finds it too risky for the subject to be included in the study",{"count":78,"type":20},30,[80],"PHASE3","This clinical trial examines whether Dronabinol, which contains the synthetic psychoactive compound tetrahydrocannabinol (THC), can alleviate severe breathlessness in patients with severe and very severe chronic obstructive pulmonary disease (COPD).",[83,27,84],"COPD","Cannabis",[86,87,84,83,27],"Randomized, Controlled, Double-blind, Crossover trial","Cannabis-based medicine","2026-04-16",{"date":90,"type":32},"2026-04-17",{"date":92,"type":32},"2025-02-26",{"date":94,"type":20},"2026-10",{"name":96,"class":39},"Vejle Hospital",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":49,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":21,"phases":106,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":68},"100614569","mindfulness-oriented-respiratory-distress-symptom-intervention-for-lung-cancer-100614569","NCT07281300","Mindfulness-Oriented Respiratory Distress Symptom Intervention for Lung Cancer","Mindfulness-Oriented Respiratory Distress Symptom Intervention for Patients With Lung Cancer: A Feasibility Randomized Controlled Trial","Inclusion Criteria:\n\n* HK patients who can understand Cantonese, aged 18 years or older;\n* A confirmed diagnosis of an intrathoracic malignancy, including small cell lung cancer, non-small cell lung cancer, or mesothelioma; at any stage of cancer treatment or palliative care;\n* Self-reported impact on daily life from at least two of the three symptoms, where one symptom is breathlessness;\n* Stability of COPD, if present;\n* WHO Performance Status of 0-2;\n* fMRI can be conducted;\n* Expected lifespan of more than six months.\n\nExclusion Criteria:\n\n* Cognitive impairments, severe psychotic symptoms, or other medical conditions that might hinder participation;\n* Participating in mindfulness or other psychological support interventions or symptom management interventions.",{"count":105,"type":20},64,[23],"Lung cancer is the leading cause of cancer mortality, posing a critical public health challenge in both Hong Kong and global populations. Patients with lung cancer frequently experience a distressing symptom cluster characterized by breathlessness-driven respiratory distress, accompanied by persistent cough and fatigue, which collectively impose a substantial disease burden. While our research team leader previously developed and validated a multi-component Respiratory Distress Symptom Intervention (RDSI) in England, demonstrating clinical efficacy for lung cancer management, its impact on psychological distress (anxiety and depression) proved limited. This limitation may reflect insufficient integration of psychological components, a crucial consideration given the well-established bidirectional relationship between respiratory symptoms and psychological distress. Emerging evidence indicates that mindfulness interventions provide dual therapeutic benefits by improving patient adherence and effectively addressing both physical symptoms, such as breathlessness and fatigue, as well as psychological distress, including anxiety and depression. Meanwhile, current evaluation methodologies have mainly focused on behavioral data collection, such as self-reported questionnaires, to reflect the effect before and after the intervention. Neuroimaging data can help understand the brain mechanisms underlying breathlessness and elucidate the effectiveness of interventions, thereby improving intervention strategies.",[109,27,110,111,112,113],"Symptom Cluster","Coughing","Fatigue Symptom","Lung Cancer Patients","Brain Activity","2026-04-14",{"date":90,"type":32},{"date":117,"type":32},"2025-08-12",{"date":119,"type":20},"2027-07-30",{"name":121,"class":39},"The Hong Kong Polytechnic University",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":21,"phases":131,"briefSummary":132,"conditions":133,"keywords":137,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":68},"100626227","assessing-the-effectiveness-of-large-language-model-llm-enabled-nurse-treatment-planning-in-2-indian-districts-100626227","NCT07432893","Assessing the Effectiveness of Large Language Model (LLM)-Enabled Nurse Treatment Planning in 2 Indian Districts","Assessing the Effectiveness of Large Language Model (LLM)-Enabled Nurse Treatment Planning in 2 Indian Districts: A Pilot Study","Inclusion Criteria:\n\n1. Adults aged ≥18 years\n2. Presenting to participating primary care facilities in study sites\n3. Meeting criteria for at least one of the following conditions or symptoms:\n\n   * Hypertension: Known diagnosis\n   * Diabetes mellitus: Known diagnosis or laboratory evidence (HbA1c ≥6.5%, fasting blood glucose ≥126 mg\u002FdL, or post-prandial glucose ≥200 mg\u002FdL)\n   * Fever: Presenting as chief complaint\n   * Breathlessness: Presenting as chief complaint, without evidence of fever\n   * Musculoskeletal pain: Presenting as chief complaint, without evidence of fever\n4. Able and willing to provide written informed consent\n5. Willing to participate in two sequential consultations and complete an exit survey\n\nExclusion Criteria:\n\n1. Inability to provide informed consent due to cognitive impairment (e.g., dementia or intellectual disability)\n2. Medical instability or condition requiring immediate emergency referral\n3. Prior participation in the study during an earlier visit",{"count":130,"type":20},672,[23],"The goal of this clinical trial is to learn whether AI-enabled, nurse-led treatment planning can improve the quality of clinical reasoning and management compared with standard physician-led care in adult primary care patients (≥18 years) presenting with hypertension, diabetes mellitus, fever, breathlessness, or musculoskeletal pain in rural and semi-urban India.\n\nThe main questions it aims to answer are:\n\n* Does a nurse + large language model (LLM) consultation achieve non-inferior clinical quality scores compared with a standard doctor consultation?\n* Is AI-assisted nurse-led care acceptable and satisfactory to patients in primary healthcare settings? Researchers will compare nurse + LLM-led consultations with physician-led standard-of-care consultations within the same participant to see if the AI-enabled nurse model delivers comparable or improved clinical reasoning and treatment planning.\n\nParticipants will:\n\n* Receive two sequential consultations for the same visit (one with a nurse using an AI tool and one with a physician, order randomized).\n* Have both consultations audio recorded for blinded clinical quality assessment.\n* Complete a brief exit survey on communication, trust, and satisfaction after the AI-assisted nurse consultation.",[134,135,27,136],"Hypertension","Diabete Mellitus","Fever",[138,139,140,141,142],"Artificial Intelligence","Delivery of Health Care","Health Personnel","Frontline Workers","Resource-Limited Settings","2026-02-19",{"date":145,"type":32},"2026-02-25",{"date":147,"type":32},"2026-01-13",{"date":149,"type":20},"2026-07-31",{"name":151,"class":39},"Sarah Nabia",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":21,"phases":162,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":166,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":40},"100625321","multicomponent-breathlessness-and-physical-activity-intervention-in-people-with-asthma-using-a-digital-platform-100625321","NCT07421115","Multicomponent Breathlessness and Physical Activity Intervention in People With Asthma Using a Digital Platform","Multicomponent Breathlessness and Physical Activity Intervention in People With Moderate to Severe Asthma Using a Supported Digital Platform","BRAID","Inclusion Criteria:\n\n* Aged 18 years or older\n* Able to provide informed consent\n* Evidence of variable airflow limitation within the past 10-years to confirm asthma diagnosis\n* Meets diagnostic criteria for moderate, or severe asthma\n* Reports breathlessness impacting daily life physical activities (modified Medical Research Council \\[mMRC\\] dyspnoea score ≥1) within the past 1-week\n* Owns a smart device with internet access, which they are willing and able to use for the study duration\n\nExclusion Criteria:\n\n* High dependence on medical care\n* Significant life-limiting comorbidity (\\\u003C12 months life expectancy)\n* Cognitive impairment, poor English language skills or significant untreated hearing impairment that prevents completion of data collection forms or understanding of verbal instructions\n* Current participation in any other clinical trial, or participation in another clinical trial within the 4-weeks preceding study entry.",{"count":161,"type":20},300,[23],"Treating breathlessness could help people with asthma have fewer symptoms and be more physically active. People with asthma report that it is important to deal with breathlessness during physical activity programs, but past research hasn't focused on this need.\n\nThe investigators have developed a multicomponent digitally supported intervention targeting breathlessness and physical inactivity. This study will test whether the multicomponent digital supported intervention will help people with asthma. The main question the study aims to answer is:\n\nDoes the multicomponent digitally supported intervention improve quality of life?\n\nParticipants will:\n\n* Be allocated to the intervention or usual care. Allocation to either group will be random (like tossing a coin).\n* Attend study visits to complete an assessment involving questionnaires and measurements\n* Receive telephone calls to ask questions about health\n* Be invited to take part in an interview to have a conversation about thoughts on participating in the study\n* Be asked to provide consent to collect information from Services Australia regarding use of health care services and medications",[165,27],"Asthma (Diagnosis)","NOT_YET_RECRUITING","2026-02-16",{"date":143,"type":32},{"date":170,"type":20},"2026-03-01",{"date":172,"type":20},"2028-10-01",{"name":174,"class":39},"University of Newcastle, Australia",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":179,"acronym":180,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":182,"targetDuration":4,"studyType":21,"phases":184,"briefSummary":185,"conditions":186,"keywords":190,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":207},"100617598","breathlessness-diagnostics-in-a-box-biab-for-primary-care-a-multi-country-quality-improvement-project-using-a-randomized-stepped-wedge-design-100617598","NCT07320703","\"Breathlessness Diagnostics in a Box\" (BiaB) for Primary Care. A Multi-country Quality Improvement Project Using a Randomized Stepped-wedge Design","BiaB","The study aims to capture the real-world heterogeneity in primary care practices and patients. Therefore, inclusion and exclusion criteria are limited.\n\nInclusion criteria\n\n* Patient must be at least 18 years old at the time of signing the informed consent.\n* Patients that present with undiagnosed dyspnea (breathlessness); or Patients who have existing diseases that could cause breathlessness, but have residual or increasing breathlessness that could be caused by other not yet detected diseases. Or HCP has doubts or requires additional tests to confirm diagnosis or to suspect new, parallel, diagnoses. For example, breathlessness in patients assessed within the framework of Cardiovascular Risk Management or for COPD monitoring\n\nExclusion criteria\n\n1. Acute worsening of previous diagnosed chronic disease where there is no suspicion of comorbidities (for example when a patient with clear COPD diagnosis has an exacerbation where typically the HCP will not perform additional tests).\n2. Inability to understand and sign the written consent form.",{"count":183,"type":20},900,[23],"This prospective stepped-wedge study evaluates whether use of the Breathlessness diagnostics in a Box (BiaB) tool shortens the time to diagnosis in patients presenting with breathlessness, compared with usual care. The study is conducted in general practice settings in the Netherlands, Spain, and Portugal. Participating sites start with a usual care period and transition sequentially to the BiaB intervention period. Data are collected during routine clinical visits, from electronic medical records, and through questionnaires completed by patients and healthcare professionals.",[27,187,188,189],"Cardiovascular","Pulmonary","Mental Disease",[191,192,193,194,195,196],"breathlessness","diagnostics","cardiovascular disease","pulmonary disease","mental disease","cardiopulmonary risk","2026-01-06",{"date":199,"type":32},"2026-01-07",{"date":201,"type":32},"2024-08-05",{"date":203,"type":20},"2027-04",{"name":205,"class":206},"General Practitioners Research Institute","NETWORK",3]